Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy

Key Points

• To evaluate the impact of early PCSK9 inhibitor use on patient outcomes following endovascular therapy for acute stroke.
• Evaluated patients with acute large vessel occlusion receiving endovascular therapy.
• Assessed the correlation between PCSK9 inhibitor use and outcomes at 90 days.
• Monitored for adverse events during the treatment.
• Reduced early adverse reactions (EAR) associated with PCSK9 inhibitor use.
• Improved 90-day outcomes noted for patients treated early with PCSK9 inhibitors.
• No additional adverse events linked to the use of PCSK9 inhibitors.

Abstract